Excess energy intake causes obesity, which leads to insulin resistance and various other complications of metabolic syndrome, including diabetes, atherosclerosis, dyslipidemia, and nonalcoholic fatty liver disease. Although recent studies have depicted altered lipid metabolism as an underlying feature, the detailed mechanisms are still unclear. Here we describe a possible role in high-fat diet (HFD)-induced obesity for monoacylglycerol lipase (MGL), an enzyme that is also known to hydrolyze the endocannabinoid 2-arachidonoylglycerol in brain. MGLdeficient [MGL-knockout (KO)] mice fed a HFD gained less body weight than wild-type mice and were protected from insulin resistance and hepatic steatosis. Food intake and energy expenditure were not altered in MGL-KO mice, but blood triglyceride levels after oral olive oil gavage were suppressed, indicating a role for MGL in intestinal fat absorption. Experiments with cannabinoid receptor type 1 (CB 1 )/MGL double-KO mice revealed that these phenotypes may include mechanisms that are independent of CB 1 -receptor-mediated endocannabinoid functions. We also noted that MGL-KO mice had less preference for HFD over normal chow diet. Oral but not intraperitoneal lipid administration strongly suppressed the appetites of MGL-KO and CB 1 /MGL double-KO mice, but not of wildtype and CB 1 -KO mice. Appetite suppression was reversed by vagotomy, suggesting involvement of MGL in the gut-brain axis regulation of appetite. Our results provide mechanistic insights of MGL's role in diet-induced obesity, lipid metabolic disorder, and regulation of appetite.-Yoshida, K., Kita, Y., Tokuoka, S. M., Hamano, F., Yamazaki, M., Sakimura, K., Kano, M., Shimizu, T. Monoacylglycerol lipase deficiency affects diet-induced obesity, fat absorption, and feeding behavior in CB 1 cannabinoid receptor-deficient mice. FASEB J. 33, 2484-2497 (2019). www.fasebj.org KEY WORDS: metabolic syndrome • satiety • adipose tissue • liver • intestine
Monoacylglycerol lipase (MGL, EC 3.1.1.23) is an enzyme that hydrolyzes monoacylglycerol (MG) to produce free fatty acid (FA) and glycerol. MGL is known to be involved in endocannabinoid catabolism in the CNS, where it degrades 2-arachidonoylglycerol (2-AG), an endogenous ligand for cannabinoid receptors. MGL-deficient [MGLknockout (KO)] mice exhibit abnormal accumulation of 2-AG in the CNS, which causes functional antagonization of cannabinoid receptor type 1 (CB 1 ) (1). MGL-KO mice showed normal physiologic and behavioral responses, but effects of cannabinoid receptor agonists on pain tolerance and catalepsy were diminished, indicating that the MGL deficiency impaired CB 1 signaling (2) .
Besides in the CNS, MGL is highly expressed in fat metabolizing tissues such as liver and adipose tissue. In these peripheral tissues, MGL may be involved in hydrolysis of various MG species. MGs are intermediate metabolites in triglyceride (TG) catabolism and are involved in energy homeostasis. TG catabolism in adipose tissue is initiated by adipose TG lipase, producing FA and diacylglycerol (DG) (3) . DG is further hydrolyzed by hormone-sensitive lipase (HSL) to produce MG and FA, and finally MGL hydrolyzes MG to complete the TG catabolism (3) .
Analyses of MGL-KO mice have demonstrated a role for MGL in energy homeostasis. Chanda et al. (2) reported that MGL-KO mice fed normal diet had less body weight than wild-type (WT) mice. Taschler et al. (4) reported impaired lipolysis as well as attenuation of high-fat diet (HFD)-induced insulin resistance, but not obesity, in MGL-KO mice. In a more recent study, Douglass et al. (5) reported that MGL-KO mice fed a HFD gained less body weight compared to WT control animals, which contrasted with the results of Taschler Besides MGL-KO mice, studies using transgenic mice have been reported. While overexpression of MGL in the forebrain resulted in a lean phenotype with increased energy cost of activity (7) , overexpression in the small intestine caused fat accumulation, increased food intake, and decreased energy consumption (8) . These reports collectively depict distinct or opposite roles of MGL in the CNS and a peripheral tissue. Thus, increasing evidence demonstrates MGL's roles in energy homeostasis; however, their details are still controversial, and more study of the underlying mechanisms is required.
In the present study, we aimed to explore in more detail the roles for MGL in the development of diet-induced obesity and associated complications. To this end, we analyzed the effects of MGL deficiency using MGL-KO and WT mice; further, to examine which effects include CB 1 -independent mechanisms, we also compared CB 1 -KO mice to CB 1 /MGL-DKO mice. Our results indicate that MGL is involved in the development of obesity, fatty liver, and insulin resistance, with a mechanism or mechanisms possibly in part independent of CB 1 -receptor-mediated endocannabinoid functions. We found that delayed intestinal lipid absorption in MGL-KO mice was CB 1 receptor independent. Further, we report a possible role for MGL in the gut-brain axis in regulation of postprandial appetite, which was also independent of the CB 1 -receptor-mediated endocannabinoid functions.
MATERIALS AND METHODS

Chemicals and reagents
Arachidonic acid (AA), 2-AG, oleoylethanolamide (OEA), arachidonoylethanolamide (AEA), AA-d8, 2-AG-d8, 38:4 DG-d8, OEA-d4, and AEA-d8 were purchased from Cayman Chemicals (Ann Arbor, MI, USA). 17:0 MG, 18:1 MG, 34:1 DG, and 38:4 DG were from Avanti Polar Lipid (Alabaster, AL, USA). Oleic acid was from MilliporeSigma (Burlington, MA, USA). The 2 H 2 O and H 2 18 O were purchased from Isotec (MilliporeSigma). JZL184 was from Cayman Chemicals. Olive oil, tyloxapol, and bovine serum albumin were from MilliporeSigma. Other chemicals of research grade were purchased from Wako Pure Chemical Industries (Osaka, Japan).
Animals MGL-KO mice (9) , CB 1 -KO mice (10) , and their control mice as specified in each experiment were prepared by mating respective heterozygous mice. For experiments that compare CB 1 /MGL-DKO mice with CB 1 -KO mice, CB 1 -KO/MGL-hetero mice were mated (11) . The MGL-KO and CB 1 /MGL-DKO mouse lines were maintained separately. Male mice were used for all the studies. All mouse lines had a C57BL/6 genetic background and were maintained in a specific-pathogen-free facility (ambient temperature of ;22°C, regular light-dark cycle of 12-h light/dark) and fed ad libitum with a standard laboratory diet (MF; Oriental Yeast, Tokyo, Japan) and water. Throughout the study, body weight and food intake were recorded by manual handling of the mice and/or animal cages.
Diet-induced obesity model
Six-week-old mice maintained on a normal chow diet were subjected to HFD-induced obesity model. High Fat Diet 32 (HFD32; 32% fat by weight; 5.076 kcal/g; CLEA-Japan, Tokyo, Japan) was used in the study, using MF (5.1% fat by weight; 3.59 kcal/g; Oriental Yeast) as a control normal chow diet. Daily food intake was determined by measuring food consumption. Body weight was monitored weekly.
Pair-feeding experiment
For the pair-feeding experiment, daily ad libitum food intake of HFD after switching from normal chow in MGL-KO mice was measured in a pretest. On the basis of the result, 6-wk-old MGL-KO mice and WT mice were fed limited amounts of HFD on d 1 to 5 (2.0, 2.5, 3.0, 3.5, and 3.5 g/mouse, respectively). Thereafter, mice were fed a HFD ad libitum and monitored for food intake and body weight.
Energy expenditure
Energy expenditure of MGL-KO and WT mice were estimated by measuring CO 2 consumption using a doubly labeled water method (12, 13) . Twelve-week-old MGL-KO and WT mice were intraperitoneally injected with 40 ml/g body weight of saline containing 50% 2 H 2 O and 5% H 2 18 O. After 2 h, the first blood sample was collected from the tail vein for determination of initial plasma heavy water levels (d 0), which was also used for determination of total body water. Then blood samples were collected every 24 h until d 4. Determination of plasma 2 H 2 O and H 2
18
O levels by a gas chromatography/mass spectrometrybased method was performed as described by Castro-Perez et al. (14) and Rachdaoui et al. (15) , respectively, with minor modifications. From initial body water amount and decay rate of 2 H 2 O and H 2 18 O, CO 2 consumption rate was calculated.
Histologic analysis
Gonadal visceral adipose tissue and liver of mice fed a HFD for 8 wk were removed and fixed with 10% formalin (Mildform; Wako). Paraffin-embedded sections were made and stained with hematoxylin and eosin for inspection. For Oil Red O staining of small intestine, mice before and 6 h after oral olive oil gavage were humanely killed, and ileum was removed and fixed with 10% formalin. Then paraffin-embedded sections were made and stained with Oil Red O (MilliporeSigma) according to the manufacturer's instructions. For image acquisition and quantification, the BZ-X700 microscope system (Keyence, Tokyo, Japan) was used. Average adipocyte areas were determined by averaging averaged adipocyte area of a mouse, which was determined by measuring all adipocytes in a 1-mm 2 microscopic field per mouse using BZ-X700 software.
Real-time quantitative PCR
Total RNA from mouse tissues were prepared using the Isogen Total RNA Extraction Kit (Nippon Gene, Tokyo, Japan). They were further purified using the RNeasy Mini Kit (Qiagen, Hilden, Germany) to obtain a total RNA without genomic DNA contamination. Using 1 mg of the purified total RNA as a template, cDNA was synthesized using Superscript III Reverse Transcriptase (Thermo Fisher Scientific, Waltham, MA, USA) and oligo-dT primers (Thermo Fisher Scientific). Real-time quantitative PCR was carried out with gene-specific primers and a LightCycler FastStart DNA Master SYBR Green I Kit (Roche Applied Science, Penzberg, Germany) using a LightCycler 1.5 system (Roche Applied Science) according to the manufacturer's instructions. The following target gene-specific primers were used: 36B4, 59-GTCCTGGCATTGTCTGTGGAG-39 (forward) and 59-GACTCTTCCTTTGCTTCAGCTTTG-39 (reverse); Mgll, 59-CAGAGAGGCCAACCTACTTTTC-39 (forward) and 59-AT-GCGCCCCAAGGTCATATTT-39 (reverse); Emr1, 59-GGCTT-CAGTGGGATGTACAGATG-39 (forward) and 59-TGAAA-GTTGGTTTGTCCATTGCT-39 (reverse); Cd68, 59-CTCCCTGT-GTGTCTGATCTTGCT-39 (forward) and 59-CTGTGCTTTCT-GTGGCTGTAGGT-39 (reverse); Itgax, 59-CAGACATTGCAG-AAAAAGGTGTTG-39 (forward) and 59-GATAAGAGGGAC-GGGGTTGTG-39 (reverse); Tnfa, 59-CCAGACCCTCACACT-CAGATCAT-39 (forward) and 59-TGGCACCACTAGTTGGTT-GTCTT-39 (reverse); Ccl2, 59-CCACTCACCTGCTGCTACT-CATT-39 (forward) and 59-CAGCACAGACCTCTCTCTTGAGC-39 (reverse); Tgfb1, 59-CCTATATTTGGAGCCTGGACACAC-39 (forward) and 59-GCTTGCGACCCACGTAGTAGA-39 (reverse); Acta2, 59-TCCCTGGAGAAGAGCTACGAAC-39 (forward) and 59-TGACAGGACGTTGTTAGCATAGAGA-39 (reverse); Col1a1, 59-GAACCCCAAGGAAAAGAAGCAC-39 (forward) and 59-GTGGACATTAGGCGCAGGAA-39 (reverse); Col6a3, 59-AGCA-CACCGAGCATCCAGTT-39 (forward) and 59-GTCCACACA-AGTCCCAGCATC-39 (reverse).
Insulin tolerance test and oral glucose tolerance test
Before insulin tolerance test and oral glucose tolerance test, food was withheld from mice for 4 or 16 h, respectively. Mice were either intraperitoneally injected with 0.75 U/kg insulin (Novolin R; Novo Nordisk Pharma, Tokyo, Japan) or orally administered 1.5 g/kg body weight of 15% (w/v) D-(+)-glucose, and blood glucose levels were measured by Glutest Neo Super (Sanwa Kagaku Kenkyusho, Aichi, Japan).
Lipid absorption test
Mice (8 wk old) were unfed for 4 h, then orally administered with 200 ml of olive oil by intragastric gavage. Blood samples were collected from tail vein using heparin-coated glass microcapillaries, and plasma TG levels were determined by LabAssay Triglyceride kit (Wako) according to the manufacturer's instructions. In experiments evaluating lipid absorption under inhibition of lipoprotein lipase, food was withheld from mice for 16 h, and tyloxapol (500 mg/kg body weight) was intraperitoneally administered just before olive oil gavage. In experiments to measure intraperitoneal lipid absorption, food was withheld from mice for 16 h, pretreated with tyloxapol for 2 h, and then intraperitoneally injected with 200 ml of Intralipid 20% fat emulsion (Fresenius Kabi Japan, Tokyo, Japan).
Determination of MG hydrolase activity
Tissues were homogenized in ice-cold extraction buffer containing 100 mM Tris pH 8.0, 250 mM sucrose, 20 mM DTT, 1 mM EDTA, and Complete Protease Inhibitor (Roche Applied Science) using a Physcotron homogenizer (Microtec, Chiba, Japan). The homogenate was centrifuged at 9000 g for 10 min at 4°C, and the supernatant was used as an enzyme source. After protein concentration was determined by Bio-Rad Protein Assay Kit (Bio-Rad, Hercules, CA, USA), the enzyme source was diluted by the homogenization buffer to a protein concentration of 100 mg/ml. To 20 ml of the sample, 5 ml of 100 mM JZL184 (MGL inhibitor) or vehicle (DMSO) was added, and incubated for 10 min at 37°C. To start the reaction, 25 ml of substrate 2-AG (200 mM) was added and incubated for 10 min at 37°C. The reaction was terminated by adding 1 ml of methanol containing deuterium-labeled AA (AA-d8, 100 ng/ml). The sample was diluted with 3 v/v of 0.03% formic acid-water and loaded onto an Oasis HLB solid phase extraction cartridge (1 cc/10 mg size; Waters, Milford, MA, USA). The solid phase extraction cartridge was washed serially with 0.03% formic acid-water, 15% ethanol-0.03% formic acid-water, and petroleum ether, and eluted in 200 ml of acetonitrile. MG hydrolase activity was determined by quantifying reaction product AA in the sample by liquid chromatographytandem mass spectrometry. Acquity UPLC (Waters) connected to a TSQ Quantum Ultra Mass Spectrometer (Thermo Fisher Scientific) was operated in selected ion monitoring mode to detect AA and AA-d8 (m/z 303 and 311, respectively, in negative ion mode). Quantification was performed by an internal standard method using multiple levels of AA solution of known concentrations. Data analysis including peak detection, integration, and quantification was performed by Xcalibur 2.0 software (Thermo Fisher Scientific).
Intestinal lipid analysis
For analysis of intestinal lipids, mice were humanely killed, and the small intestine was removed, snap frozen under liquid nitrogen, and stored at 280°C until analysis. The frozen tissues were powdered using SK-100 mill (Tokken, Chiba, Japan), and total lipids were extracted by the Bligh-Dyer method (16) after adding internal standards (AA-d8, 17:0 MG, 2-AG-d8, 38:4 DG-d8, AEA-d8, and OEA-d4) as needed. For TG determination, the extracts were evaporated using a centrifugal vacuum evaporator and then reconstituted in 2-propanol:Triton X-100 (9:1 v/v). TG levels were measured by the LabAssay Triglyceride Kit (Wako). For determination of MGs, DGs, FAs, and N-acylethanolamines, the extracts were reconstituted in methanol and subjected to solid phase extraction as described. A Liquid Chromatography-Mass Spectrometry (LCMS)-8040 liquid chromatography-tandem mass spectrometry system (Shimadzu, Kyoto, Japan) was operated in selected reaction monitoring mode for detection of 17:0 MG (m/z 343→269), 
Fecal lipid analysis
Feces were collected from MGL-KO and WT mice fed a normal chow diet or a HFD for 8 wk. Total lipids were extracted by the Bligh-Dyer method and derivatized with the Fatty Acid Methylation Kit (Nakalai Tesque, Kyoto, Japan) to obtain total FAs as methyl esters. FA levels were quantified using GC-2010 Plus gas chromatography with flame ionization detector. Sum of FAs (C16-C22) were calculated as total FAs.
Food preference test
Before starting a food preference test, mice were individually housed in a cage with 2 food trays (multifeeder; Shinfactory, Fukuoka, Japan), both filled with normal chow diet for 3 d for habituation. Then 1 food tray was switched to a HFD, so that the mouse could freely choose either a normal chow diet or a HFD, and daily food consumption was monitored for 7 d.
Feeding behavior after olive oil gavage
After 16 h of subjection to food withdrawal, mice (8 wk old) were administered 200 ml of either olive oil or saline by intragastric gavage or else were intraperitoneally injected with 200 ml of either 20% Intralipid or saline. For 4 h after these procedures, mice had ad libitum access to water but did not have access to food. Then food access was provided (normal chow, ad libitum), and food ingestion was monitored for 6 h. In experiments using vagotomized mice, mice (6 wk old) were vagotomized under stereomicroscopy by cutting the gastric branches of vagus nerve while preserving hepatic branch. After a recovery period of 7 to 10 d, the mice were subjected to the test described above. Shamoperated mice, which received all procedures except for the cutting of the vagus nerve, were used as control animals.
Statistical analysis
GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA) was used for statistical calculations. A value of P , 0.05 was considered statistically significant.
Ethics statement
All procedures in the present study were conducted in accordance with the Guidelines for Animal Care of The University of Tokyo, which was approved by the Animal Experimentation Committee of Faculty of Medicine, The University of Tokyo (M-P13-027).
RESULTS
HFD-induced obesity in MGL-KO mice
Previous studies have reported conflicting results for the consequence of MGL deletion in a HFD-induced obesity model (4, 5) . Therefore, we performed similar experiments using MGL-KO and WT mice. When fed a normal chow diet, MGL-KO mice had similar body weight gain, food intake, and energy expenditure compared to WT mice ( Fig. 1A, B , E), consistent with previous reports (4, 5) . When fed a HFD, MGL-KO mice showed significantly less body weight gain compared to WT mice ( Fig. 1A) . Food intake of mice fed a HFD was similar between genotypes, but in MGL-KO mice, we found a transient decrease until d 5 (Fig. 1C ). To examine whether this transient decrease in food intake accounts for the decreased body weight gain in MGL-KO mice, we performed pair-feeding experiments, in which food intake of WT mice was adjusted to that of MGL-KO mice. MGL-KO mice gained less body weight under pair-feeding conditions, demonstrating that MGL-KO mice were resistant to obesity independent of the transient decrease in food intake ( Fig. 1D ). Histologic analysis demonstrated that after 8 wk of HFD treatment, WT mice had a number of large lipid droplets in their livers, which were not obvious in MGL-KO mice (Fig. 1F ). Enlarged adipocytes and signs of macrophage infiltration were observed in the visceral adipose tissue of WT but not MGL-KO mice (Fig. 1G, H) . Expression levels of Cd68 (encoding CD68 protein, a macrophage marker), Ccl2 (MCP-1, a macrophage-attracting chemokine), and Tnfa (TNF-a, a proinflammatory cytokine) in the adipose tissue were low in MGL-KO mice compared to WT control animals, indicating less macrophage infiltration in the MGL-KO mice (Fig. 1I ). In line with these observations, and also consistent with previous reports (4, 5), MGL-KO mice showed improved glucose tolerance and insulin sensitivity ( Fig. 1J , K).
Fat accumulation in liver and adipose tissue after long-term HFD treatment
In a HFD-induced obesity model, it has been shown that prolonged HFD treatment promotes adipose tissue remodeling that includes involution of expanded visceral fat, leading to ectopic fat accumulation in the liver (17) . To examine the possible involvement of MGL in this process, we monitored WT and MGL-KO mice that were fed a HFD for longer durations.
Consistent with the results from the short-term HFD regimen, MGL-KO mice gained significantly less body weight after long-term HFD administration compared to WT mice ( Fig. 2A) . However, the relative difference of body weights became less as the mice were fed for a longer period. MGL-KO mice weighed ;18% less than WT mice after 6 wk, but only 13% less after 24 wk of HFD, respectively (Figs. 1A and 2A); and MGL-KO mice also became obese, weighing .42 g on average at 24 wk ( Fig. 2A) .
Increase in liver weight, which was prominent in WT mice, was substantially attenuated in MGL-KO mice ( Fig.  2B ), suggesting protection from fatty liver. In agreement with this, gross tissue examination showed that MGL-KO mice have less fat accumulation in the liver when fed a long-term HFD (Fig. 2C ). Gene expression analysis of Emr1 (F4/80, macrophage marker), Cd68 (macrophage marker), Itgax (CD11c, M1-macrophage or dendritic cell marker), Tnfa, Ccl2, Tgfb1 (TGF-b1, profibrogenic cytokine), Acta2 (actin, profibrotic marker), and Col1a1 and Col6a3 (collagens, profibrotic markers) suggested that MGL-KO mice were also protected from HFD-induced hepatic inflammation and fibrosis ( Fig. 2D ).
We then wondered whether any differences or changes that take place in the adipose tissue can explain the protected liver in MGL-KO mice. After 8 wk of eating a HFD, MGL-KO mice had significantly less visceral fat amounts compared to WT mice ( Fig. 2E ). Whereas visceral fat amounts decreased at later time points after wk 8 in WT mice, visceral fat amounts continued to increase in MGL-KO mice so that they exceeded the amounts in WT mice at 12 and 24 wk ( Fig. 2E ). We also found that the macrophage marker genes Emr1 and Cd68 were less up-regulated in visceral fat of MGL-KO mice compared to WT mice after 24 wk of being fed a HFD (Fig. 2F ), indicating blunted inflammatory response despite visceral fat accumulation. We performed the insulin tolerance test on 24 wk HFD-fed mice, and as shown in Fig. 2G , MGL-KO mice showed improved responses to insulin compared to WT control animals.
Collectively, these results demonstrate that loss of MGL results in altered adipose remodeling and protection from fatty liver during HFD-induced obesity, and improved glucose homeostasis at the chronic phase.
HFD-induced obesity in CB 1 /MGL-DKO mice
MGL deficiency increases 2-AG levels in the CNS, which results in a down-regulation and desensitization of CB 1 receptor (1). Because CB 1 -KO mice are lean and gain less body weight when fed a HFD (18, 19) , it is possible that the phenotypes of MGL-KO mice that we observed may be explained by altered CB 1 signaling. To test this, we performed a HFD-induced obesity model in CB 1 /MGL-DKO mice, using CB 1 -KO siblings as a control group. CB 1 -KO mice fed a HFD showed slower body weight increase ( Figs. 1A and 3A ) and less food intake (Figs. 1C and 3B) compared to WT mice, which reproduced previous findings (18, 19) . CB 1 /MGL-DKO mice gained less body weight compared to control CB 1 -KO mice despite similar food intake, demonstrating that additional MGL deletion on CB 1 -KO mice affords protection from HFD-induced obesity (Fig. 3A, B) . Comparison of body weights of WT, MGL-KO, CB 1 -KO, and CB 1 /MGL-DKO mice 6 and 12 wk after eating a HFD demonstrated that the deletion of MGL and CB 1 tends to have additive effects on the reduction of body weight, which was significant at 12 wk of being fed a HFD (Fig. 3C ). This suggests that MGL and CB 1 each provide an at least partly independent contribution for body weight gain. After HFD feeding, CB 1 /MGL-DKO mice had improved glucose tolerance and insulin responses compared to CB 1 -KO mice (Fig. 3D, E) . These results demonstrate that a CB 1 receptor-independent downstream mechanism of MGL may play roles in the development of obesity and insulin resistance. Interestingly, the transient decrease in food intake we observed in MGL-KO mice was also found in CB 1 /MGL-DKO mice but not in control CB 1 -KO mice (Fig. 3B ), suggesting that this behavioral phenotype occurred completely independent of the CB 1 -receptormediated endocannabinoid functions.
Intestinal lipid absorption of MGL-KO mice
Altered body weight gain during HFD feeding may be explained by altered energy intake, energy expenditure, or both. For example, behavioral (feeding and exercise) and metabolic (gastrointestinal absorption, energy storage, and heat production) factors can modulate the balance.
Because MGL-KO mice showed less body weight gain when fed a HFD despite similar food intake and energy expenditure, we wondered if there was any difference in fat absorption.
We first analyzed fecal fat in WT and MGL-KO mice fed normal chow or a HFD. As shown in Fig. 4A , fecal fat contents were higher in HFD-fed mice compared to normal chow-fed mice, but no significant difference was found between WT and MGL-KO mice, suggesting that gross fat absorption was comparable.
We next examined fat absorption of MGL-KO and WT mice by monitoring plasma TG levels after oral olive oil gavage. Plasma TG levels of WT mice showed a transient increase that peaked at 2 h after olive oil administration, reflecting TG secretion from intestine to circulation followed by lipoprotein lipase-dependent TG uptake from circulation to tissues (Fig. 4B) . In MGL-KO mice, the peak TG level was significantly lower than that observed in WT mice, although the time profile was not altered (Fig. 4B ). Next, we performed similar experiments under inhibition of lipoprotein lipase with tyloxapol to block clearance of TGs from circulation (20) . In this condition, plasma TG levels increased gradually even without olive oil administration, presumably reflecting hepatic fat secretion (Fig. 4C ). Upon olive oil gavage, a large increase in plasma TG was observed in WT mice but was nearly absent in MGL-KO mice (Fig. 4C) . A similar result was obtained in CB 1 /MGL-DKO mice compared to CB 1 -KO mice (Fig. 4D) . When lipid was injected intraperitoneally, robust increases in plasma TGs were observed in both MGL-KO and WT mice (Fig. 4E) . Together, these results support that intestinal fat absorption is specifically altered by MGL deficiency. We examined MGL expression in the small intestine. Although gene expression analysis indicated relatively low MGL expression in the small intestine ( Fig. 4F) , in vitro enzyme assays of tissue extracts demonstrated that the small intestine contains MG hydrolase activity comparable to the brain (Fig. 4G, H) , ;50% of which was attributable to MGL (Fig. 4H ). This result was compatible with the hypothesis that MGL expressed in the small intestine play roles in lipid absorption.
Next, to analyze intestinal lipid absorption in more detail, we measured TG contents at two different sites of the small intestine: jejunum and ileum. In WT mice, tissue TG levels peaked at 2 h after olive oil gavage in both sites, then decreased by 6 h (Fig. 4I, J) . However, in MGL-KO mice, TG levels remained at higher levels compared to WT mice 6 h after gavage, especially in the ileum (Fig. 4J ). In agreement with this result, stronger Oil Red O signals were found within the ileum of MGL-KO mice compared to WT mice 6 h after gavage (Fig. 4K) . These results indicate that the lack of MGL caused a prolonged TG retention in the small intestine.
Feeding behavior of MGL-KO and CB 1 /MGL-DKO mice
The transient decreases in food intake upon switching to a HFD, which we observed in both MGL-KO and CB 1 / MGL-DKO mice (Figs. 1C and 3B ), suggested that MGL may modulate feeding behavior in a CB 1 -independent manner. To examine if this phenotype arose from an altered preference for HFD, we performed a food preference test. Mice were presented with two food trays containing either normal chow or HFD, and food intake was monitored. In contrast to WT mice, which showed a strong preference for HFD ( Fig. 5A) , MGL-KO mice did not show a clear preference for HFD; rather, MGL-KO mice preferred normal chow at d 1, and then gradually adapted to take some HFD (Fig. 5B ). When the same experiment was performed to compare CB 1 /MGL-DKO vs. CB 1 -KO mice, both of these groups showed initial preferences for normal chow over HFD (Fig. 5C, D) , suggesting a dominant role for CB 1 on palatable food preference.
We next examined the possibility that MGL affects satiety after fat intake. After olive oil gavage, voluntary food intake was strongly suppressed in MGL-KO mice compared to WT control animals (Fig. 5E ). A similar pattern was observed when CB 1 /MGL-DKO mice were compared to CB 1 -KO mice, indicating the phenotype was CB 1 independent (Fig. 5F ). We found that intraperitoneal lipid (20% Intralipid) injection did not suppress food intake (Fig.  5G ), suggesting that intestinal lipid absorption is critical for this phenotype. Intestinal hormones released after food intake are known to exert anorexigenic effects in the brain through the vagus nerve (21-23). To examine the involvement of the gut-brain axis, we analyzed vagotomized mice. As shown in Fig. 5H , food intake after olive oil gavage was significantly recovered in vagotomized MGL-KO mice compared to sham-operated control animals. These results demonstrate that the altered feeding behavior in MGL-KO mice is at least partly mediated by the gut-brain axis of appetite regulation.
MGL deficiency may alter intestinal lipid metabolism, which may affect satiety upon fat intake. To test this, we analyzed intestinal lipid profiles before and 2 h after olive oil administration in WT and MGL-KO mice ( Fig. 5I-P) . We focused on oleic acid (18:1)-related and AA (20:4)related lipids because oleates are the major fatty acyl species in olive oil, and endocannabinoids (2-AG and AEA) affect satiety (18, 19) . In an unfed condition, MG and DG levels were significantly, or tended to be, higher in MGL-KO mice compared to WT mice (Fig. 5I-L) . This observation was consistent with a previous report describing MG accumulations in various tissues by blocking MGL (24) . In this condition, FAs and N-acylethanolamine levels were not different between genotypes ( Fig. 5M-P) . Upon olive oil gavage, increases in oleic acid-related lipids (18:1 MG, 34:1 DG, OEA, and oleic acid) were noted in both WT and MGL-KO small intestine ( Fig. 5I, K, M, O) , while such an increase was not found in arachidonate-related lipid species (Fig. 5J , L, N, P). None of the lipid species increased by olive oil gavage was significantly different between genotypes.
Thus, so far examined, we did not find candidate lipids associable with altered satiety upon olive oil gavage.
DISCUSSION
Previous reports have described two distinct functions of MGL in vivo: regulation of endocannabinoid tone in the CNS and TG catabolism in the peripheral tissues (2, 4, 5, 25) . In the present study, we investigated the CB 1 dependency of the roles for MGL in these functions using mouse models of HFD-induced obesity and associated complications.
Our result that MGL deficiency afforded protection from HFD-induced obesity in both MGL-KO and CB 1 /MGL-DKO mice (Figs. 1A and 3A) suggested a CB 1 -independent aspect of MGL in this process. It has been shown that MGL-KO mice have significantly reduced lipolysis in adipose tissue upon b3-adrenergic agonist stimulation (4), suggesting MGL's role in FA mobilization. However, consequences of altered lipolysis on energy homeostasis are difficult to predict, and phenotypes of mice deficient for other lipolytic enzymes varies: adipose TG lipase KO mice were obese (26), while HSL-KO mice were protected from obesity (27) . Although the phenotype of MGL-KO mice we observed resembles that reported in HSL-KO mice in resistant to obesity, we did not observe increased energy consumption in MGL-KO mice, as was reported in HSL-KO mice.
Besides FA, glycerol is a lipolytic product of MGL during MG hydrolysis, differentiating this enzyme from other lipolytic enzymes. Mice deficient for aquaporin 7, a glycerol permeable channel expressed in adipose tissue, showed impaired glycerol release in response to b3adrenergic agonists, had low plasma glycerol levels, and displayed adult-onset obesity (28) . Thus, altered glycerol levels by the deletion of MGL may also play roles in obesity.
Although in the present study we describe a CB 1independent role for MGL in HFD-induced obesity, it is important to consider that the effects of MGL deletion also depend on the endocannabinoid system, especially as CB 1 receptor functions are reported to be down-regulated in MGL-KO mice (1), and CB 1 -KO mice are also protected from HFD-induced obesity (18, 19) . It is important to note that increased 2-AG may activate CB 2 , another endocannabinoid receptor. There are several lines of evidence that activation of CB 2 is beneficial to obesity and obesityrelated metabolic disorders (29) (30) (31) . MGL deletion may elevate basal CB 2 activity in various peripheral tissues expressing this receptor subtype, including liver, adipose tissue, and intestine, though such possibilities were not examined in the present study. Also, recent studies demonstrate that transient receptor potential cation channel subfamily V member 1 (TRPV1) cation channels are activated by 2-AG (32, 33) . Because roles for TRPV1 in lipid metabolism and obesity have been suggested (34, 35) , it is possible that deletion of MGL may cause activation of TRPV1 channels to alter energy metabolism. Relative contributions of CB 1 -dependent and -independent mechanisms in detail should be determined in future studies using conditional gene knockout/knockdown strategies that selectively target CNS or peripheral tissues.
In a long-term (24 wk) HFD feeding regimen, we observed protection from fatty liver in MGL-KO mice accompanied by improved insulin responses even though MGL-KO mice also gained body weight, albeit slightly less than the WT control animals ( Fig. 2A, B, G) . We also found that the amounts of visceral fat continued to increase in MGL-KO mice at 12 and 24 wk of HFD, while WT control animals displayed fat involution ( Fig. 2E ). We hypothesize that MGL deletion protects mice from adipose remodeling, maintaining their lipid storing capacities at higher levels than WT control animals, which consequently protects the mice from fat accumulation and inflammation in the liver. The higher visceral fat accumulation in MGL-KO mice in later periods was somewhat paradoxical in that, in general, accumulation of visceral fat is considered deleterious for metabolic syndrome and/or cardiovascular disease (36) . This may be explained in part from our finding that expression levels of inflammatory genes in the visceral fat and the liver were lower in MGL-KO mice compared to WT control animals (Fig. 2D, F) ; increased visceral fat may not be so deleterious for metabolic syndrome or cardiovascular disease until it becomes inflammatory or adipose remodeling takes place. It has been suggested that in HFDinduced obesity, increased levels of circulating free FAs exert toxic effects on various tissues, such as muscle, liver, adipose tissue, and pancreas, leading to insulin resistance (37) . Although previous reports on adipose TG lipase and HSL enzymes have demonstrated their major lipolytic roles (26, 38) , MGL may also contribute to lipolysis in vivo (4). Thus, a possible mechanism by which MGL may promote adipose remodeling and fatty liver is through generation of toxic lipolytic products.
In the present study, we have demonstrated a role for MGL in intestinal fat absorption. Upon food intake, dietary TGs are digested by pancreatic lipase to MG and FA, which may then be absorbed by the small intestine. In enterocytes of the small intestine, TG is resynthesized from MG and FA by the activities of acyl-CoA:MG acyltransferases (MGATs), acyl-CoA:DG acyltransferases (DGATs), and acyl-CoA synthetases (39) . Currently known mechanisms of gastrointestinal fat digestion and absorption do not involve MG hydrolysis, and roles for MGL have not been documented until a recent report demonstrated delayed intestinal fat absorption in MGL-KO mice (5) .
We reproduced the observation that an increase of blood TG after oral olive oil gavage was strikingly suppressed in MGL-KO mice (5) (Fig. 4C ). In addition, our data using CB 1 /MGL-DKO mice clearly demonstrated that CB 1 is not involved in this phenotype (Fig. 4D) . The possibility that the suppressed blood TG after oral olive oil gavage was due to increased TG clearance from the bloodstream is excluded for two reasons. First, intraperitoneally administered lipid caused a large increase of blood TG levels in MGL-KO mice that was comparable to those seen in WT control animals ( Fig.  4E) . Second, when mice were not pretreated with tyloxapol, blood TG levels peaked at 2 h after olive oil gavage in both WT-and MGL-KO mice, suggesting similar postprandial responses for TG clearance from the bloodstream (Fig. 4B) . Therefore, the phenotype appears attributable to altered intestinal function.
Our results for TG contents in jejunum and ileum demonstrate that TG levels reached a plateau similarly in both WT and MGL-KO mice 2 h after olive oil gavage, suggesting similar intestinal lipid uptake (Fig. 4I, J) , as has also been previously reported (5) . At 6 h after olive oil gavage, we found that the TG levels decreased in WT but remained high in MGL-KO ileum, suggesting delayed lipid clearance from the small intestine ( Fig. 4J, K) .
It is noteworthy that deletion of either MGAT2 or DGAT1, enzymes involved in TG synthesis, resulted in similar phenotypes to MGL-KO mice: both MGAT2deficient mice and DGAT1-deficient mice exhibited quantitatively normal but delayed lipid absorption upon oral fat gavage, despite unimpaired TG synthesis (40) (41) (42) . Although the mechanism of how MGL is involved in intestinal fat clearance remains unclear, overall, these results suggest that proper intestinal neutral lipid metabolism is critical for TG secretion into circulation.
A recent study reported that pharmacological inhibition of MGL impaired gut motility, causing prolonged whole-gut transit time in WT but not CB 1 -KO mice (43) . This indicates that MGL may regulate peripheral endocannabinoid functions including gut motility and hence energy intake. However, that study also reported that MGL-KO mice had normal whole-gut transit as a result of down-regulation of CB 1 receptor functions (43) . Collectively, MGL may regulate both gut motility and lipid absorption via endocannabinoid-dependent and -independent mechanisms, respectively.
Although our results clearly demonstrate a prolonged intestinal lipid absorption in MGL-KO mice, it does not directly explain the reduced obesity in these mice, as total energy intakes were unchanged (Fig. 1B,  C) . Nevertheless, it is possible that lower peak blood TG levels after olive oil gavage in MGL-KO mice (Fig. 4B ) may be beneficial for metabolic disorders, as postprandial hyperlipidemia has been reportedly linked with low-grade inflammatory disease, including obesity, diabetes, and atherosclerosis (44) .
A role for the endocannabinoid system in determining appetites and body weight has been demonstrated. The CB 1 antagonist SR141716 (Rimonabant) has been used as an anorexigenic antiobesity drug in humans, but it was withdrawn as a result of psychiatric adverse events (45) . In mice, CB 1 deletion impairs HFD preferences (18) . In this context, MGL may affect energy intake and body weight through modulating endocannabinoid tone.
In the present study, interestingly, we found that feeding behavior after oral olive oil gavage was altered in both MGL-KO and CB 1 /MGL-DKO mice, but not in CB 1 -KO mice (Fig. 5E-G) . Because vagotomy rescued the phenotype of MGL-KO mice, we concluded that MGL may affect the gut-brain axis regulation of feeding behavior ( Fig. 5H ). Despite this finding, it should also be noted that altered feeding behavior does not explain the reduced obesity in MGL-KO mice, as HFD intakes were mostly comparable between MGL-KO and WT mice (Fig.  1C) . Although a transient decrease until d 5 after switching to HFD was found in MGL-KO mice when fed ad libitum (Fig. 1C) , a pair-feeding experiment demonstrated that reduced obesity in MGL-KO mice is independent of altered food intake (Fig. 1D) . Given that the phenotype is CB 1 independent, alternative downstream mechanisms, including activation of CB 2 and/or TRPV1 channels by increased 2-AG, as they have been reported to suppress food intake (46, 47) , or other mechanisms triggered by MGs or MG metabolites should be examined; these await future study. Regarding appetite regulation by gastrointestinal tract, several anorexigenic hormones are known to be released from gut upon food intake and gastrointestinal transit (48) . For example, glucagon-like peptide 1 (GLP-1) and peptide YY are known to transform information to the brain via the vagus nerve (21) (22) (23) . Whether MGL affects feeding behavior by these factors or by other mechanisms remains unknown, but several possibilities exist. Nelson et al. (42) have reported mice with a similar phenotype in which an intestine-specific deletion of MGAT2 caused a transient reduction in food intake upon switching from normal chow to a HFD. Because both MGL-KO and MGAT2-KO mice accumulate MG in tissues, MG or its metabolites may suppress the postprandial appetite. There are reports describing that 2-oleoylglycerol (2-OG) stimulates GLP-1 production in the small intestine (49, 50) , and 2-OG may therefore be one of the candidate anorexigenic lipids that may accumulate in both MGL-KO and MGAT2-KO mice. Though more detailed examination is needed, our data failed to support this hypothetical role for 2-OG, as intestinal 18:1 MG levels after fat intake were similarly high in both genotypes (Fig. 5I) . Also, our preliminary result for plasma GLP-1 levels 2 h after olive oil gavage did not show a difference between WT and MGL-KO mice (data not shown).
OEA is another intestinal lipid reportedly possessing anorexigenic effects (51, 52) . Intestinal OEA is produced from dietary oleic acid (52) . A recent report described reduced appetite for fat in rats fed a HFD that had undergone gastric bypass surgery. This was due to a HFD-induced augmentation of the OEA production in the lower small intestine (53) . The delayed lipid absorption in MGL-KO mice may also alter availability of oleic acid in the lower small intestine, which might also affect OEA levels to modulate appetite. In our hands, OEA levels were similar in WT and MGL-KO mice, both at the basal condition and upon olive oil gavage (Fig. 5O) . Thus, our data did not suggest OEA as a candidate lipid. However, considering that our analysis covered only a limited part of the small intestine (jejunum) and time points (before and 2 h after fat intake), more comprehensive lipidome and peptide analyses may be necessary.
In summary, our study using CB 1 /MGL-DKO mice together with MGL-KO mice adds insight into the mechanistic roles of MGL in the development of HFD-induced obesity and associated complications, intestinal fat absorption, and feeding behavior, demonstrating diverse functions through CB 1 -dependent and -independent mechanisms. At the same time, however, the present study has a limitation in that the use of a global KO mouse model does not provide tissue-or cell type-specific information on MGL. More detailed understanding of these mechanisms, especially of intestinal lipid absorption and feeding behavior, awaits future studies using tissue-or cell typespecific MGL-KO and/or MGL-overexpressing mice.
